C57BL/6JCya-Rev3lem1/Cya
Common Name
Rev3l-KO
Product ID
S-KO-17672
Backgroud
C57BL/6JCya
Strain ID
KOCMP-19714-Rev3l-B6J-VA
When using this mouse strain in a publication, please cite “Rev3l-KO Mouse (Catalog S-KO-17672) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Rev3l-KO
Strain ID
KOCMP-19714-Rev3l-B6J-VA
Gene Name
Product ID
S-KO-17672
Gene Alias
Rev, Rev3, Sez4
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 10
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000019986
NCBI RefSeq
NM_011264
Target Region
Exon 2
Size of Effective Region
~1.3 kb
Overview of Gene Research
REV3L, encoding the catalytic subunit of DNA polymerase ζ (Pol ζ), is crucial for error-prone translesion synthesis (TLS), a DNA damage tolerance mechanism. TLS helps cells bypass DNA lesions, protecting them from potentially harmful DNA damage, yet it also poses a risk to genome stability due to its error-prone nature [3,4,5,6,7,9].
Multiple studies have shown the significance of REV3L in cancer. In the population of Jammu and Kashmir, three REV3L single-nucleotide variants (rs1002481, rs462779, and rs465646) were significantly associated with an increased risk of non-small cell lung cancer (NSCLC) under the recessive model [1]. In NSCLC H1299 cells, cisplatin induced REV3L expression, and overexpression of REV3L conferred cisplatin resistance, while knockdown sensitized the cells to cisplatin treatment, suggesting REV3L as a potential target for NSCLC chemotherapy [2]. Similar roles were found in esophageal squamous cell carcinoma, gliomas, and cervical cancer, where REV3L was upregulated, associated with tumor progression and chemoresistance [3,5,6]. In myelodysplastic syndrome, a REV3L mutation (c.9253-6T>C) was associated with poor prognosis [8]. Also, in non-small-cell lung cancer, circular RNA PRMT5 promoted cisplatin-resistance via the miR-4458/REV3L axis [10].
In conclusion, REV3L plays a key role in DNA damage tolerance through TLS. Its dysregulation is associated with various cancers, contributing to tumor progression and chemoresistance. Understanding the function of REV3L through these studies provides potential diagnostic and therapeutic targets for multiple cancer types.
References：
1. Jamwal, Rajeshwer Singh, Mahajan, Nikita, Bhat, Gh Rasool, Kumar, Rakesh, Bhat, Audesh. 2021. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir. In Cancer epidemiology, 75, 102047. doi:10.1016/j.canep.2021.102047. https://pubmed.ncbi.nlm.nih.gov/34655923/
2. Wang, Wenjie, Sheng, Wenjiong, Yu, Chenxiao, Zhang, Huojun, Zhang, Shuyu. 2015. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. In Oncology reports, 34, 1460-8. doi:10.3892/or.2015.4121. https://pubmed.ncbi.nlm.nih.gov/26165320/
3. Zhu, Xiaozhong, Zou, Shitao, Zhou, Jundong, Wu, Jinchang, Chen, Yihong. 2016. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma. In Oncology reports, 35, 1664-70. doi:10.3892/or.2016.4549. https://pubmed.ncbi.nlm.nih.gov/26752104/
4. Tirman, Stephanie, Quinet, Annabel, Wood, Matthew, Zou, Lee, Vindigni, Alessandro. . Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. In Molecular cell, 81, 4026-4040.e8. doi:10.1016/j.molcel.2021.09.013. https://pubmed.ncbi.nlm.nih.gov/34624216/
5. Wang, Huibo, Zhang, Shu-Yu, Wang, Shuai, Lu, Daru, Zhao, Shiguang. . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. In Neuro-oncology, 11, 790-802. doi:10.1215/15228517-2009-015. https://pubmed.ncbi.nlm.nih.gov/19289490/
6. Yang, Li, Shi, Tingyan, Liu, Fei, Yang, Gong, Cheng, Xi. 2015. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. In PloS one, 10, e0120334. doi:10.1371/journal.pone.0120334. https://pubmed.ncbi.nlm.nih.gov/25781640/
7. Halas, Agnieszka, Fijak-Moskal, Jolanta, Kuberska, Renata, Sledziewska-Gojska, Ewa, Płoski, Rafał. 2021. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant. In Journal of molecular medicine (Berlin, Germany), 99, 415-423. doi:10.1007/s00109-020-02033-3. https://pubmed.ncbi.nlm.nih.gov/33474647/
8. Oliveira, Roberta Taiane G de, França, Ivo Gabriel F, Junior, Howard L R, Magalhães, Silvia M M, Pinheiro, Ronald F. 2020. c.9253-6T>c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome. In Hematology, transfusion and cell therapy, 43, 377-381. doi:10.1016/j.htct.2020.05.006. https://pubmed.ncbi.nlm.nih.gov/32682781/
9. Wang, Fengting, Li, Pan, Shao, Yuan, Xiao, Wei, Li, Xialu. . Site-specific proteolytic cleavage prevents ubiquitination and degradation of human REV3L, the catalytic subunit of DNA polymerase ζ. In Nucleic acids research, 48, 3619-3637. doi:10.1093/nar/gkaa096. https://pubmed.ncbi.nlm.nih.gov/32064513/
10. Pang, Jun, Ye, Liwen, Zhao, Dan, Zhao, Ding, Chen, Qingwei. 2020. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. In Cell biology international, 44, 2416-2426. doi:10.1002/cbin.11449. https://pubmed.ncbi.nlm.nih.gov/32808744/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.